Skipper He
About
In The Last Decade
Skipper He
36 papers receiving 904 citations
Peers
Comparison fields: 5 of 93
- Oncology 512
- Molecular Biology 446
- Cancer Research 204
- Pulmonary and Respiratory Medicine 161
- Hematology 155
Countries citing papers authored by Skipper He
This map shows the geographic impact of Skipper He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Skipper He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Skipper He more than expected).
Fields of papers citing papers by Skipper He
This network shows the impact of papers produced by Skipper He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Skipper He. The network helps show where Skipper He may publish in the future.
Co-authorship network of co-authors of Skipper He
This figure shows the co-authorship network connecting the top 25 collaborators of Skipper He. A scholar is included among the top collaborators of Skipper He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Skipper He. Skipper He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Relationship between tumor stem cell heterogeneity and responsiveness to chemotherapy. | 10 |
| 2 | Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect. | 49 |
| 3 | Establishment of cross-resistance profiles for new agents. | 92 |
| 4 | Experimental therapeutics and kinetics: selection and overgrowth of specifically and permanently drug-resistant tumor cells. | 54 |
| 5 | Basic and therapeutic trial results obtained in the spontaneous AK leukemia (lymphoma) model-end of 1971. | 23 |
| 6 | A quick reference chart on cross resistance between anticancer patients. | 10 |
| 7 | Success and failure in the treatment of solid tumors. I. Effects of cyclophosphamide (NSC-26271) on primary and metastatic plasmacytoma in the hamster. | 27 |
| 8 | Chemotherapy of leukemia L1210 by 6-mercaptopurine (NSC-755) in combination with 6-methylthiopurine ribonucleoside (NSC-40774). | 4 |
| 9 | Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells. | 178 |
| 10 | Experimental evaluation of potenital anticancer agents. XVII. Kinetics of growth and regression after treatment of certain solid tumors. | 35 |
| 11 | EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIV. FURTHER STUDY OF CERTAIN BASIC CONCEPTS UNDERLYING CHEMOTHERAPY OF LEUKEMIA. | 53 |
| 12 | Experimental evaluation of potential anticancer agents. X. A specificity test for distinguishing false positives. | 2 |
| 13 | Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia. | 257 |
| 14 | Experimental evaluation of potential anticancer agents. II. Studies on the growth characteristics, metastases, and drug response of hamster neoplasms of diverse "sites of origin". | 7 |
| 15 | Experimental evaluation of potential anticancer agents. I. Quantitative therapeutic evaluation of certain purine analogs. | 23 |
| 16 | Observations of the retiring chairman of the Cancer Chemotherapy Review Board. | 2 |
| 17 | The inhibition of growth of sarcoma 180 by combinations of B6-antagonists and acid hydrazides. | 11 |
| 18 | Studies on the mechanism of action and anticancer activity of N-methylformamide. | 17 |
| 19 | Effects of a series of tumor-inhibiting agents and related compounds on L1210 leukemia and drug-resistant lines thereof. | 8 |
| 20 | Observations on the anticancer activity of 6-mercaptopurine. | 41 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.